Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 140

1.

Assessing the inter-observer variability of Computer-Aided Nodule Assessment and Risk Yield (CANARY) to characterize lung adenocarcinomas.

Nakajima EC, Frankland MP, Johnson TF, Antic SL, Chen H, Chen SC, Karwoski RA, Walker R, Landman BA, Clay RD, Bartholmai BJ, Rajagopalan S, Peikert T, Massion PP, Maldonado F.

PLoS One. 2018 Jun 1;13(6):e0198118. doi: 10.1371/journal.pone.0198118. eCollection 2018.

2.

A Phenome-Wide Association Study Uncovers a Role for Autoimmunity in the Development of Chronic Obstructive Pulmonary Disease.

Ji X, Niu X, Qian J, Martucci V, Pendergrass SA, Gorlov IP, Amos CI, Denny JC, Massion PP, Aldrich MC.

Am J Respir Cell Mol Biol. 2018 Jun;58(6):777-779. doi: 10.1165/rcmb.2017-0409LE. No abstract available.

PMID:
29856256
3.

xCT (SLC7A11)-mediated metabolic reprogramming promotes non-small cell lung cancer progression.

Ji X, Qian J, Rahman SMJ, Siska PJ, Zou Y, Harris BK, Hoeksema MD, Trenary IA, Heidi C, Eisenberg R, Rathmell JC, Young JD, Massion PP.

Oncogene. 2018 May 23. doi: 10.1038/s41388-018-0307-z. [Epub ahead of print]

PMID:
29789716
4.

Lifetime Smoking History and Risk of Lung Cancer: Results From the Framingham Heart Study.

Tindle HA, Stevenson Duncan M, Greevy RA, Vasan RS, Kundu S, Massion PP, Freiberg MS.

J Natl Cancer Inst. 2018 May 16. doi: 10.1093/jnci/djy041. [Epub ahead of print]

PMID:
29788259
5.

p52 expression enhances lung cancer progression.

Saxon JA, Yu H, Polosukhin VV, Stathopoulos GT, Gleaves LA, McLoed AG, Massion PP, Yull FE, Zhao Z, Blackwell TS.

Sci Rep. 2018 Apr 17;8(1):6078. doi: 10.1038/s41598-018-24488-8.

6.

Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.

Wood DE, Kazerooni EA, Baum SL, Eapen GA, Ettinger DS, Hou L, Jackman DM, Klippenstein D, Kumar R, Lackner RP, Leard LE, Lennes IT, Leung ANC, Makani SS, Massion PP, Mazzone P, Merritt RE, Meyers BF, Midthun DE, Pipavath S, Pratt C, Reddy C, Reid ME, Rotter AJ, Sachs PB, Schabath MB, Schiebler ML, Tong BC, Travis WD, Wei B, Yang SC, Gregory KM, Hughes M.

J Natl Compr Canc Netw. 2018 Apr;16(4):412-441. doi: 10.6004/jnccn.2018.0020.

PMID:
29632061
7.

Next-generation molecular therapy in lung cancer.

Qian J, Massion PP.

Transl Lung Cancer Res. 2018 Feb;7(Suppl 1):S31-S34. doi: 10.21037/tlcr.2018.01.03. No abstract available.

8.

RNAseq analysis of bronchial epithelial cells to identify COPD-associated genes and SNPs.

Yeo J, Morales DA, Chen T, Crawford EL, Zhang X, Blomquist TM, Levin AM, Massion PP, Arenberg DA, Midthun DE, Mazzone PJ, Nathan SD, Wainz RJ, Nana-Sinkam P, Willey PFS, Arend TJ, Padda K, Qiu S, Federov A, Hernandez DR, Hammersley JR, Yoon Y, Safi F, Khuder SA, Willey JC.

BMC Pulm Med. 2018 Mar 5;18(1):42. doi: 10.1186/s12890-018-0603-y.

9.

Assessment of Plasma Proteomics Biomarker's Ability to Distinguish Benign From Malignant Lung Nodules: Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial.

Silvestri GA, Tanner NT, Kearney P, Vachani A, Massion PP, Porter A, Springmeyer SC, Fang KC, Midthun D, Mazzone PJ; PANOPTIC Trial Team.

Chest. 2018 Mar 1. pii: S0012-3692(18)30307-6. doi: 10.1016/j.chest.2018.02.012. [Epub ahead of print]

10.

Complement C4d-specific antibodies for the diagnosis of lung cancer.

Ajona D, Okrój M, Pajares MJ, Agorreta J, Lozano MD, Zulueta JJ, Verri C, Roz L, Sozzi G, Pastorino U, Massion PP, Montuenga LM, Blom AM, Pio R.

Oncotarget. 2017 Dec 26;9(5):6346-6355. doi: 10.18632/oncotarget.23690. eCollection 2018 Jan 19.

11.

Communication About the Probability of Cancer in Indeterminate Pulmonary Nodules.

Maiga AW, Deppen SA, Massion PP, Callaway-Lane C, Pinkerman R, Dittus RS, Lambright ES, Nesbitt JC, Grogan EL.

JAMA Surg. 2018 Apr 1;153(4):353-357. doi: 10.1001/jamasurg.2017.4878.

PMID:
29261826
12.

Intracardiac Metastases Detected by 18F-FSPG PET/CT.

Magarik MA, Walker RC, Gilbert J, Manning HC, Massion PP.

Clin Nucl Med. 2018 Jan;43(1):28-30. doi: 10.1097/RLU.0000000000001883.

PMID:
29076915
13.

Timeliness of Care and Lung Cancer Tumor-Stage Progression: How Long Can We Wait?

Maiga AW, Deppen SA, Pinkerman R, Callaway-Lane C, Massion PP, Dittus RS, Lambright ES, Nesbitt JC, Baker D, Grogan EL.

Ann Thorac Surg. 2017 Dec;104(6):1791-1797. doi: 10.1016/j.athoracsur.2017.06.051. Epub 2017 Oct 21.

PMID:
29033012
14.

Evaluating Molecular Biomarkers for the Early Detection of Lung Cancer: When Is a Biomarker Ready for Clinical Use? An Official American Thoracic Society Policy Statement.

Mazzone PJ, Sears CR, Arenberg DA, Gaga M, Gould MK, Massion PP, Nair VS, Powell CA, Silvestri GA, Vachani A, Wiener RS; ATS Assembly on Thoracic Oncology.

Am J Respir Crit Care Med. 2017 Oct 1;196(7):e15-e29. doi: 10.1164/rccm.201708-1678ST.

PMID:
28960111
15.

Identification of Proteomic Features To Distinguish Benign Pulmonary Nodules from Lung Adenocarcinoma.

Codreanu SG, Hoeksema MD, Slebos RJC, Zimmerman LJ, Rahman SMJ, Li M, Chen SC, Chen H, Eisenberg R, Liebler DC, Massion PP.

J Proteome Res. 2017 Sep 1;16(9):3266-3276. doi: 10.1021/acs.jproteome.7b00245. Epub 2017 Aug 8.

PMID:
28731711
16.

Single Cell Analysis of Human Tissues and Solid Tumors with Mass Cytometry.

Leelatian N, Doxie DB, Greenplate AR, Mobley BC, Lehman JM, Sinnaeve J, Kauffman RM, Werkhaven JA, Mistry AM, Weaver KD, Thompson RC, Massion PP, Hooks MA, Kelley MC, Chambless LB, Ihrie RA, Irish JM.

Cytometry B Clin Cytom. 2017 Jul 18. doi: 10.1002/cyto.b.21542. [Epub ahead of print] No abstract available.

PMID:
28719730
17.

Immunotherapy and Targeted Therapy for Small Cell Lung Cancer: There Is Hope.

Lehman JM, Gwin ME, Massion PP.

Curr Oncol Rep. 2017 Jul;19(7):49. doi: 10.1007/s11912-017-0609-2. Review.

PMID:
28643173
18.

A 3q gene signature associated with triple negative breast cancer organ specific metastasis and response to neoadjuvant chemotherapy.

Qian J, Chen H, Ji X, Eisenberg R, Chakravarthy AB, Mayer IA, Massion PP.

Sci Rep. 2017 Apr 7;7:45828. doi: 10.1038/srep45828.

19.

Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis.

Gardner EE, Lok BH, Schneeberger VE, Desmeules P, Miles LA, Arnold PK, Ni A, Khodos I, de Stanchina E, Nguyen T, Sage J, Campbell JE, Ribich S, Rekhtman N, Dowlati A, Massion PP, Rudin CM, Poirier JT.

Cancer Cell. 2017 Feb 13;31(2):286-299. doi: 10.1016/j.ccell.2017.01.006.

20.

68Ga-DOTATATE PET/CT imaging of indeterminate pulmonary nodules and lung cancer.

Walker R, Deppen S, Smith G, Shi C, Lehman J, Clanton J, Moore B, Burns R, Grogan EL, Massion PP.

PLoS One. 2017 Feb 9;12(2):e0171301. doi: 10.1371/journal.pone.0171301. eCollection 2017.

21.

Novel Hybrid Phenotype Revealed in Small Cell Lung Cancer by a Transcription Factor Network Model That Can Explain Tumor Heterogeneity.

Udyavar AR, Wooten DJ, Hoeksema M, Bansal M, Califano A, Estrada L, Schnell S, Irish JM, Massion PP, Quaranta V.

Cancer Res. 2017 Mar 1;77(5):1063-1074. doi: 10.1158/0008-5472.CAN-16-1467. Epub 2016 Dec 8.

22.

Secretory IgA Deficiency in Individual Small Airways Is Associated with Persistent Inflammation and Remodeling.

Polosukhin VV, Richmond BW, Du RH, Cates JM, Wu P, Nian H, Massion PP, Ware LB, Lee JW, Kononov AV, Lawson WE, Blackwell TS.

Am J Respir Crit Care Med. 2017 Apr 15;195(8):1010-1021. doi: 10.1164/rccm.201604-0759OC.

23.

The airway epithelium undergoes metabolic reprogramming in individuals at high risk for lung cancer.

Rahman SM, Ji X, Zimmerman LJ, Li M, Harris BK, Hoeksema MD, Trenary IA, Zou Y, Qian J, Slebos RJ, Beane J, Spira A, Shyr Y, Eisenberg R, Liebler DC, Young JD, Massion PP.

JCI Insight. 2016 Nov 17;1(19):e88814.

24.

Inhibition of the Biosynthesis of Prostaglandin E2 By Low-Dose Aspirin: Implications for Adenocarcinoma Metastasis.

Boutaud O, Sosa IR, Amin T, Oram D, Adler D, Hwang HS, Crews BC, Milne G, Harris BK, Hoeksema M, Knollmann BC, Lammers PE, Marnett LJ, Massion PP, Oates JA.

Cancer Prev Res (Phila). 2016 Nov;9(11):855-865. Epub 2016 Aug 23.

25.

The Pursuit of Noninvasive Diagnosis of Lung Cancer.

Atwater T, Cook CM, Massion PP.

Semin Respir Crit Care Med. 2016 Oct;37(5):670-680. Epub 2016 Oct 12. Review.

26.

Radiological Image Traits Predictive of Cancer Status in Pulmonary Nodules.

Liu Y, Balagurunathan Y, Atwater T, Antic S, Li Q, Walker RC, Smith GT, Massion PP, Schabath MB, Gillies RJ.

Clin Cancer Res. 2017 Mar 15;23(6):1442-1449. doi: 10.1158/1078-0432.CCR-15-3102. Epub 2016 Sep 23.

27.

Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer.

Massion PP, Healey GF, Peek LJ, Fredericks L, Sewell HF, Murray A, Robertson JF.

J Thorac Oncol. 2017 Mar;12(3):578-584. doi: 10.1016/j.jtho.2016.08.143. Epub 2016 Sep 8.

28.

Single cell analysis of human tissues and solid tumors with mass cytometry.

Leelatian N, Doxie DB, Greenplate AR, Mobley BC, Lehman JM, Sinnaeve J, Kauffmann RM, Werkhaven JA, Mistry AM, Weaver KD, Thompson RC, Massion PP, Hooks MA, Kelley MC, Chambless LB, Ihrie RA, Irish JM.

Cytometry B Clin Cytom. 2017 Jan;92(1):68-78. doi: 10.1002/cyto.b.21481. Epub 2016 Oct 4.

29.

Fluorescence-based measurement of cystine uptake through xCT shows requirement for ROS detoxification in activated lymphocytes.

Siska PJ, Kim B, Ji X, Hoeksema MD, Massion PP, Beckermann KE, Wu J, Chi JT, Hong J, Rathmell JC.

J Immunol Methods. 2016 Nov;438:51-58. doi: 10.1016/j.jim.2016.08.013. Epub 2016 Sep 2.

30.

Differences in Patient Outcomes of Prevalence, Interval, and Screen-Detected Lung Cancers in the CT Arm of the National Lung Screening Trial.

Schabath MB, Massion PP, Thompson ZJ, Eschrich SA, Balagurunathan Y, Goldof D, Aberle DR, Gillies RJ.

PLoS One. 2016 Aug 10;11(8):e0159880. doi: 10.1371/journal.pone.0159880. eCollection 2016.

31.

Biomarkers of risk to develop lung cancer in the new screening era.

Atwater T, Massion PP.

Ann Transl Med. 2016 Apr;4(8):158. doi: 10.21037/atm.2016.03.46. Review.

32.

Accumulation of isolevuglandin-modified protein in normal and fibrotic lung.

Mont S, Davies SS, Roberts Second LJ, Mernaugh RL, McDonald WH, Segal BH, Zackert W, Kropski JA, Blackwell TS, Sekhar KR, Galligan JJ, Massion PP, Marnett LJ, Travis EL, Freeman ML.

Sci Rep. 2016 Apr 27;6:24919. doi: 10.1038/srep24919.

33.

Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

Bunn PA Jr, Minna JD, Augustyn A, Gazdar AF, Ouadah Y, Krasnow MA, Berns A, Brambilla E, Rekhtman N, Massion PP, Niederst M, Peifer M, Yokota J, Govindan R, Poirier JT, Byers LA, Wynes MW, McFadden DG, MacPherson D, Hann CL, Farago AF, Dive C, Teicher BA, Peacock CD, Johnson JE, Cobb MH, Wendel HG, Spigel D, Sage J, Yang P, Pietanza MC, Krug LM, Heymach J, Ujhazy P, Zhou C, Goto K, Dowlati A, Christensen CL, Park K, Einhorn LH, Edelman MJ, Giaccone G, Gerber DE, Salgia R, Owonikoko T, Malik S, Karachaliou N, Gandara DR, Slotman BJ, Blackhall F, Goss G, Thomas R, Rudin CM, Hirsch FR.

J Thorac Oncol. 2016 Apr;11(4):453-74. doi: 10.1016/j.jtho.2016.01.012. Epub 2016 Jan 30. Review. No abstract available.

34.

Lung cancer risk test trial: study design, participant baseline characteristics, bronchoscopy safety, and establishment of a biospecimen repository.

Crawford EL, Levin A, Safi F, Lu M, Baugh A, Zhang X, Yeo J, Khuder SA, Boulos AM, Nana-Sinkam P, Massion PP, Arenberg DA, Midthun D, Mazzone PJ, Nathan SD, Wainz R, Silvestri G, Tita J, Willey JC.

BMC Pulm Med. 2016 Jan 22;16:16. doi: 10.1186/s12890-016-0178-4.

35.

Global gene expression profiling reveals a suppressed immune response pathway associated with 3q amplification in squamous carcinoma of the lung.

Qian J, Zou Y, Wang J, Zhang B, Massion PP.

Genom Data. 2015 Jun 14;5:272-4. doi: 10.1016/j.gdata.2015.06.014. eCollection 2015 Sep.

36.

Secretory IgA from submucosal glands does not compensate for its airway surface deficiency in chronic obstructive pulmonary disease.

Du RH, Richmond BW, Blackwell TS Jr, Cates JM, Massion PP, Ware LB, Lee JW, Kononov AV, Lawson WE, Blackwell TS, Polosukhin VV.

Virchows Arch. 2015 Dec;467(6):657-665. Epub 2015 Oct 2.

37.

Reproducibility of Volumetric Computed Tomography of Stable Small Pulmonary Nodules with Implications on Estimated Growth Rate and Optimal Scan Interval.

Smith GT, Rahman AR, Li M, Moore B, Gietema H, Veronesi G, Massion PP, Walker RC.

PLoS One. 2015 Sep 17;10(9):e0138144. doi: 10.1371/journal.pone.0138144. eCollection 2015.

38.

A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo.

Saunders LR, Bankovich AJ, Anderson WC, Aujay MA, Bheddah S, Black K, Desai R, Escarpe PA, Hampl J, Laysang A, Liu D, Lopez-Molina J, Milton M, Park A, Pysz MA, Shao H, Slingerland B, Torgov M, Williams SA, Foord O, Howard P, Jassem J, Badzio A, Czapiewski P, Harpole DH, Dowlati A, Massion PP, Travis WD, Pietanza MC, Poirier JT, Rudin CM, Stull RA, Dylla SJ.

Sci Transl Med. 2015 Aug 26;7(302):302ra136. doi: 10.1126/scitranslmed.aac9459.

39.

Comprehensive genomic profiles of small cell lung cancer.

George J, Lim JS, Jang SJ, Cun Y, Ozretić L, Kong G, Leenders F, Lu X, Fernández-Cuesta L, Bosco G, Müller C, Dahmen I, Jahchan NS, Park KS, Yang D, Karnezis AN, Vaka D, Torres A, Wang MS, Korbel JO, Menon R, Chun SM, Kim D, Wilkerson M, Hayes N, Engelmann D, Pützer B, Bos M, Michels S, Vlasic I, Seidel D, Pinther B, Schaub P, Becker C, Altmüller J, Yokota J, Kohno T, Iwakawa R, Tsuta K, Noguchi M, Muley T, Hoffmann H, Schnabel PA, Petersen I, Chen Y, Soltermann A, Tischler V, Choi CM, Kim YH, Massion PP, Zou Y, Jovanovic D, Kontic M, Wright GM, Russell PA, Solomon B, Koch I, Lindner M, Muscarella LA, la Torre A, Field JK, Jakopovic M, Knezevic J, Castaños-Vélez E, Roz L, Pastorino U, Brustugun OT, Lund-Iversen M, Thunnissen E, Köhler J, Schuler M, Botling J, Sandelin M, Sanchez-Cespedes M, Salvesen HB, Achter V, Lang U, Bogus M, Schneider PM, Zander T, Ansén S, Hallek M, Wolf J, Vingron M, Yatabe Y, Travis WD, Nürnberg P, Reinhardt C, Perner S, Heukamp L, Büttner R, Haas SA, Brambilla E, Peifer M, Sage J, Thomas RK.

Nature. 2015 Aug 6;524(7563):47-53. doi: 10.1038/nature14664. Epub 2015 Jul 13.

40.

Preclinical Evaluation of 4-[18F]Fluoroglutamine PET to Assess ASCT2 Expression in Lung Cancer.

Hassanein M, Hight MR, Buck JR, Tantawy MN, Nickels ML, Hoeksema MD, Harris BK, Boyd K, Massion PP, Manning HC.

Mol Imaging Biol. 2016 Feb;18(1):18-23. doi: 10.1007/s11307-015-0862-4.

41.

Targeting SLC1a5-mediated glutamine dependence in non-small cell lung cancer.

Hassanein M, Qian J, Hoeksema MD, Wang J, Jacobovitz M, Ji X, Harris FT, Harris BK, Boyd KL, Chen H, Eisenberg R, Massion PP.

Int J Cancer. 2015 Oct 1;137(7):1587-97. doi: 10.1002/ijc.29535. Epub 2015 May 6.

42.

Chronic obstructive pulmonary disease and subsequent overall and lung cancer mortality in low-income adults.

Aldrich MC, Munro HM, Mumma M, Grogan EL, Massion PP, Blackwell TS, Blot WJ.

PLoS One. 2015 Mar 26;10(3):e0121805. doi: 10.1371/journal.pone.0121805. eCollection 2015.

43.

The RNA binding protein FXR1 is a new driver in the 3q26-29 amplicon and predicts poor prognosis in human cancers.

Qian J, Hassanein M, Hoeksema MD, Harris BK, Zou Y, Chen H, Lu P, Eisenberg R, Wang J, Espinosa A, Ji X, Harris FT, Rahman SM, Massion PP.

Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):3469-74. doi: 10.1073/pnas.1421975112. Epub 2015 Mar 2.

44.

Validation of a multiprotein plasma classifier to identify benign lung nodules.

Vachani A, Pass HI, Rom WN, Midthun DE, Edell ES, Laviolette M, Li XJ, Fong PY, Hunsucker SW, Hayward C, Mazzone PJ, Madtes DK, Miller YE, Walker MG, Shi J, Kearney P, Fang KC, Massion PP.

J Thorac Oncol. 2015 Apr;10(4):629-37. doi: 10.1097/JTO.0000000000000447.

45.

Lung cancer screening, version 1.2015: featured updates to the NCCN guidelines.

Wood DE, Kazerooni E, Baum SL, Dransfield MT, Eapen GA, Ettinger DS, Hou L, Jackman DM, Klippenstein D, Kumar R, Lackner RP, Leard LE, Leung AN, Makani SS, Massion PP, Meyers BF, Otterson GA, Peairs K, Pipavath S, Pratt-Pozo C, Reddy C, Reid ME, Rotter AJ, Sachs PB, Schabath MB, Sequist LV, Tong BC, Travis WD, Yang SC, Gregory KM, Hughes M; National comprehension cancer network.

J Natl Compr Canc Netw. 2015 Jan;13(1):23-34; quiz 34.

PMID:
25583767
46.

Extensive phenotyping of individuals at risk for familial interstitial pneumonia reveals clues to the pathogenesis of interstitial lung disease.

Kropski JA, Pritchett JM, Zoz DF, Crossno PF, Markin C, Garnett ET, Degryse AL, Mitchell DB, Polosukhin VV, Rickman OB, Choi L, Cheng DS, McConaha ME, Jones BR, Gleaves LA, McMahon FB, Worrell JA, Solus JF, Ware LB, Lee JW, Massion PP, Zaynagetdinov R, White ES, Kurtis JD, Johnson JE, Groshong SD, Lancaster LH, Young LR, Steele MP, Phillips Iii JA, Cogan JD, Loyd JE, Lawson WE, Blackwell TS.

Am J Respir Crit Care Med. 2015 Feb 15;191(4):417-26. doi: 10.1164/rccm.201406-1162OC.

47.

Indeterminate pulmonary nodules: risk for having or for developing lung cancer?

Massion PP, Walker RC.

Cancer Prev Res (Phila). 2014 Dec;7(12):1173-8. doi: 10.1158/1940-6207.CAPR-14-0364. Epub 2014 Oct 27.

48.

Accuracy of FDG-PET to diagnose lung cancer in areas with infectious lung disease: a meta-analysis.

Deppen SA, Blume JD, Kensinger CD, Morgan AM, Aldrich MC, Massion PP, Walker RC, McPheeters ML, Putnam JB Jr, Grogan EL.

JAMA. 2014 Sep 24;312(12):1227-36. doi: 10.1001/jama.2014.11488. Review.

49.

Predicting lung cancer prior to surgical resection in patients with lung nodules.

Deppen SA, Blume JD, Aldrich MC, Fletcher SA, Massion PP, Walker RC, Chen HC, Speroff T, Degesys CA, Pinkerman R, Lambright ES, Nesbitt JC, Putnam JB Jr, Grogan EL.

J Thorac Oncol. 2014 Oct;9(10):1477-84. doi: 10.1097/JTO.0000000000000287.

50.

Blockade of the programmed death-1 pathway restores sarcoidosis CD4(+) T-cell proliferative capacity.

Braun NA, Celada LJ, Herazo-Maya JD, Abraham S, Shaginurova G, Sevin CM, Grutters J, Culver DA, Dworski R, Sheller J, Massion PP, Polosukhin VV, Johnson JE, Kaminski N, Wilkes DS, Oswald-Richter KA, Drake WP.

Am J Respir Crit Care Med. 2014 Sep 1;190(5):560-71. doi: 10.1164/rccm.201401-0188OC.

Supplemental Content

Loading ...
Support Center